Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

NUDT21 Modulates Pign through APA Mechanism to Affect the Progression of MDS and AML

Jeffrey J. Pu, Fanggang Ren, Na Zhang, Shuo Li, Lan Zhang, Eric Miller, Guirong Wang, Hongwei Wang

Blood (2022) 140 (Supplement 1): 11481–11482.

https://doi.org/10.1182/blood-2022-166604

Published: 2022

Journal Articles

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139858

Published: 2020

Journal Articles

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, Josée M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMSc, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137020

Published: 2020

Journal Articles

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-137025

Published: 2020

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Cody Ashby, PhD, Eileen Boyle, Ruslana G. Tytarenko, MS, Hongwei Wang, MS, Adam Rosenthal, MS, Purvi Patel, Yan Wang, Shayu Deshpande, Maria Ortiz, Erin Flynt, Antje Hoering, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD PhD, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 110.

https://doi.org/10.1182/blood-2018-99-113045

Published: 2018

Journal Articles

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Tarun K. Garg, PhD, Katie Stone, BS, Hongwei Wang, MS, Antje Hoering, PhD, Brian A Walker, PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Faith E. Davies, MD, Gareth Morgan, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2018-99-119692

Published: 2018

Journal Articles

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N Booher, PhD, Grzegorz S. Nowakowski, MD, Krish Patel, MD, Matthew A. Lunning, DO, Maria Elena S. Samson, B.S., Ruzanna Atoyan, MD, Anna W Ma, MS, Guang-Xin Xu, BS, Steven Dellarocca, B.S., Holly Modafferi, BS, Mylissa Borek, B.S., Zhidong Zhang, PhD, Jefferson Parker, PhD, Duncan Whitney, PhD, Hongwei Wang, MD, David P Tuck, MD, Anas Younes, MD

Blood (2018) 132 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2018-99-117383

Published: 2018

Journal Articles

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood (2018) 132 (6): 587–597.

https://doi.org/10.1182/blood-2018-03-840132

Published: 2018

Includes: Supplemental data

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Hongwei Wang, MD, Fengdong Cheng, MD, Jie Cheng, PhD, Alejandro Villagra, PhD, Jianguo Tao, MD PhD, James E. Bradner, MD, Eduardo M. Sotomayor, MD

Blood (2015) 126 (23): 822.

https://doi.org/10.1182/blood.V126.23.822.822

Published: 2015

Journal Articles

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

Sarah Waheed, MD, Hongwei Wang, Pingping Qu, PhD, Christoph Heuck, MD, Aasiya Matin, Yogesh Jethava, MB, MRCP, MD FRCPath, Frits van Rhee, MD PhD, Antje Hoering, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1777.

https://doi.org/10.1182/blood.V126.23.1777.1777

Published: 2015

Journal Articles

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Fengdong Cheng, MD, Bing Xia, MD, Eva Sahakian, PhD, Tint Lwin, MD PhD, Hongwei Wang, MD, Limin Xing, MD, Bijal D. Shah, MD, Patricio PerezVillarroel, BS, Maritza LienlafMoreno, BS, Yizhuo Zhang, MD, Steven N Quayle, PhD, Simon S Jones, PhD, Javier Pinilla-Ibarz, MD PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 5397.

https://doi.org/10.1182/blood.V124.21.5397.5397

Published: 2014

Journal Articles

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Hongwei Wang, MD, Fengdong Cheng, MD, Limin Xing, MD, Xiaohong Zhao, PhD, Alejandro Villagra, PhD, Javier Pinilla-Ibarz, MD PhD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 2749.

https://doi.org/10.1182/blood.V124.21.2749.2749

Published: 2014

Journal Articles

Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy

Andressa Sodre Laino, M.S., David M Woods, Ph.D., Fengdong Cheng, MD, Hongwei Wang, MD, Eduardo M. Sotomayor, MD

Blood (2013) 122 (21): 1050.

https://doi.org/10.1182/blood.V122.21.1050.1050

Published: 2013

Journal Articles

Characteristics Of Patients Included In The Myelofibrosis Real-World Practice-Based Network Research (ENRiCH) Data Platform

Gregory Hess, Eileen Fonseca, Andrew Lee, Hongwei Wang, Ravinder Dhawan, Stephen F Thompson, Sheikh Usman Iqbal, Sean Redmond

Blood (2013) 122 (21): 1580.

https://doi.org/10.1182/blood.V122.21.1580.1580

Published: 2013

Journal Articles

Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Eva Sahakian, Ph.D, Jennifer Rock-Klotz, B.S., Bijal D. Shah, MD, John Powers, B.S., Jennifer L. Cultrera, MD, Susan Deng, David M Woods, M.S., Michael Nguyen, Fengdong Cheng, MD, Hongwei Wang, Patricio Perez-Villarroel, B.S., Maritza Lienlaf, B.S., Tesa Knox, M.S., Selina Chen-Kiang, PhD, Alejandro Villagra, PhD, Jianguo Tao, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Simon S Jones, Eduardo M. Sotomayor, MD

Blood (2012) 120 (21): 1660.

https://doi.org/10.1182/blood.V120.21.1660.1660

Published: 2012

Journal Articles

Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages

Maritza Lienlaf, BS., Patricio Perez-Villarroel, BS., Fengdong Cheng, M.D., Hongwei Wang, MD, Danay Marante, MS, Sean Yoder, MS, Woan Karrune V., PhD, Tessa Knox, MS, Stephen Lagor, Javier Pinilla-Ibarz, MD, PhD, Edward Seto, PhD, Eduardo M. Sotomayor, MD, Alejandro Villagra, PhD

Blood (2012) 120 (21): 1039.

https://doi.org/10.1182/blood.V120.21.1039.1039

Published: 2012

Journal Articles

Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype

David M Woods, M.S., Karrune V. Woan, PhD, Eva Sahakian, Ph.D, John Powers, B.S., Fengdong Cheng, MD, Hongwei Wang, Jennifer Rock-Klotz, B.S., Jeffrey S. Weber, MD, PhD, Alejandro Villagra, PhD, Javier Pinilla-Ibarz, MD, PhD, Eduardo M. Sotomayor, MD

Blood (2012) 120 (21): 840.

https://doi.org/10.1182/blood.V120.21.840.840

Published: 2012

Journal Articles

Analysis of the Impact and Burden of Illness of Myelofibrosis in the US

Hongwei Wang, Jyotsna Mehta, Usman Iqbal, Ruben A. Mesa

Blood (2012) 120 (21): 972.

https://doi.org/10.1182/blood.V120.21.972.972

Published: 2012

NARROW

NUDT21 Modulates Pign through APA Mechanism to Affect the Progression of MDS and AML

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy

Characteristics Of Patients Included In The Myelofibrosis Real-World Practice-Based Network Research (ENRiCH) Data Platform

Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages

Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype

Analysis of the Impact and Burden of Illness of Myelofibrosis in the US

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only